Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (August 2024)
36 slides from Curis's investor presentation, August 2024
Slide 1: Corporate Presentation
Corporate Presentation August 2024
Slide 2: Cautionary note regarding forward looking statements and disclaimers
Cautionary note regarding forward looking statements and disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Emavusertib is a potential first-to-market IRAK 4 inhibitor
Emavusertib is a potential first-to-market IRAK 4 inhibitor Demonstrated safety and • Being evaluated in Phase 1/2 clinical single-agent activity studies in NHL, AML, and Solid Tumors • Potential for monotherapy and combination use in NHL, AML Demonstrated synergy and Solid Tumors with BTKi, HMA, BC
Slide 4: Broad Market Opportunity in NHL, AML, and Solid Tumors
Broad Market Opportunity in NHL, AML, and Solid Tumors Significant market opportunities Additional opportunities in current development programs with NHL expansion PCNSL FLT3m AML WM MCL MZL ABC-DLBCL US Incidence per 100K 0.51 1.32 4.23 0.55 0.56 1.57 2.08 Newly Diagnosed Per Year Newly Diagnosed P
Slide 5: Emavusertib in NHL
Emavusertib in NHL fen CUS’
Slide 6: Mechanism in NHL
Mechanism in NHL Two pathways drive NF-ĸB BCR Pathway TLR Pathway (which drives B-cell lymphomas) B cell TLR1 TLR2 TLR4 TLR5 receptor TLR6 combining IRAK4i and BTKi Endosome enables dual blockade of NF-ĸB TLR7 TLR8 TLR9 ibrutinib BTK Myddosome CARD11 MYD88 MALT1 BCL10 IRAK1 IRAK4 emavusertib NF-κB o
Slide 7: Emavusertib is synergistic with BTKi in NHL
Emavusertib is synergistic with BTKi in NHL Monotherapy vs. Combination emavusertib + ibrutinib 1400 in NHL model vehicle 1200 blocking both BCR and TLR pathways has Mean Tumor Volume (mm3) + SEM 1000 been demonstrated to be more effective than blocking either one alone 800 ibrutinib emavusertib 600
Slide 8: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 9: Emavusertib safety profile in NHL
Emavusertib safety profile in NHL1 • 19 patients treated with emavusertib in 100 mg 200 mg 300 mg Total Grade 3+ TRAE in BID+IBR BID+IBR BID+IBR combination with ibrutinib in multiple NHL (N=2) (N=10) (N=7) (N=19) >1 Patient subtypes n (%) n (%) n (%) n (%) • Shown to be well tolerated with an accep
Slide 10: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 11: Single-agent activity demonstrated in NHL
Single-agent activity demonstrated in NHL Percent Change in Tumor Burden from Baseline Case Study in Dose Response (WM patient) 50 (6 patients treated for ~ 1 year or longer) mg 100 mg Reduction in tumor burden Clear Dose Response sustained with monotherapy 2950 2850 200 mg Increase in dose levels l
Slide 12: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 13: Combination data from the Ph 1 basket study in NHL presented at ASH 2023
Combination data from the Ph 1 basket study in NHL presented at ASH 2023 All patients (n=19), multiple NHL subtypes No Prior BTKi Failed Prior BTKi 0% • Heavily pre-treated patients MZL sCNS CLL MCL MCL WM WM MZL-N pCNS FL MZL-N pCNS pCNS pCNS pCNS -10% (1-10 prior lines) -20% Best % Change in Tumor
Slide 14: Strategy in NHL
Strategy in NHL ❶ Demonstrate safety 19 patients1 treated in TakeAim Lymphoma Ph 1b study, acceptable safety profile established, no overlapping dose-limiting toxicity with ibrutinib ❷ Demonstrate single-agent activity Single-agent activity demonstrated, with patients remaining on study up to 4 year
Slide 15: Additional NHL indications of interest
Additional NHL indications of interest CLL Waldenström's Macroglobulinemia • TLR signaling is highly activated in lymph node–resident CLL cells1 • MYD88 and CXCR4 mutations activate NF-ĸB through the TLR pathway TLR signature Lymph Node Peripheral Blood maximal inhibition only • Recurring mutations
Slide 16: Summary in NHL
Summary in NHL Lymphoma • Emavusertib continues to demonstrate clear anti-cancer activity in R/R PCNSL • Work with FDA to clarify registrational path and prepare for potential amendment of the current Ph 1/2 study into a study that would support an NDA filing for accelerated approval • Prioritize ad
Slide 17: Emavusertib in AML
Emavusertib in AML fen CUS’
Slide 18: Emavusertib binds to IRAK4 and FLT3, blocking both the TLR and FLT3 pathways
Emavusertib binds to IRAK4 and FLT3, blocking both the TLR and FLT3 pathways Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRAK2 >20,000 IRAK3 8,500 IRAK4 DYRK1A 23 25 Binds tightly to IRAK4 CLK 1, 2, 4 FLT3 WT 31 Haspin FLT3 (D835H) FLT3 (D835V
Slide 19: IRAK4-L is an independent and powerful driver of disease in AML
IRAK4-L is an independent and powerful driver of disease in AML IRAK4-L is expressed in nearly all AML patients IRAK4-L is oncogenic in AML 800 Knocking out IRAK4 IRAK4-L stops leukemic activity IRAK4-S (similar findings using CRISPR/CAS9) 600 Sum of IRAK4 variants Control 400 200 Smith Nat Cell Bio
Slide 20: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim AML Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path to 1st
Slide 21: Emavusertib safety profile in AML
Emavusertib safety profile in AML1 200 mg BID 300 mg BID 400 mg BID 500 mg BID Total Grade 3+ TRAE > 1 patients (n = 27) (n = 78) (n = 15) (n = 3) (n=123) • 123 patients treated with emavusertib n (%) n (%) n (%) n (%) n (%) in TakeAim Leukemia Study Number of patients having 4 (14.8) 21 (26.9) 7 (4
Slide 22: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim AML Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path to 1st
Slide 23: Single-agent activity demonstrated in AML
Single-agent activity demonstrated in AML Total AML Patients, all dose levels Subset of AML Patients treated at 300mg BID nearly all AML patients express the oncogenic isoform of IRAK4 who also have FLT3 mutation 100% 100% 80% 80% 60% Emavusertib exposure at 300 mg BID 60% Emavusertib targets both c
Slide 24: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim AML Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path to 1st
Slide 25: Emavusertib in FLT3m AML
Emavusertib in FLT3m AML fen CUS’
Slide 26: Emavusertib's dual-targeting of IRAK4 and FLT3 enables monotherapy opportunity in FLT3m AML
Emavusertib’s dual-targeting of IRAK4 and FLT3 enables monotherapy opportunity in FLT3m AML IRAKi synergy with FLT3i 100% – 75% – FLT3i Control IRAK4 inhibition overcomes adaptive resistance to FLT3i 50% – IRAKi 25% – Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective mea
Slide 27: Emavusertib is a potential best-in-class therapy in FLT3m AML
Emavusertib is a potential best-in-class therapy in FLT3m AML CR + CRh/CRi Rate 35% Salvage Line Patients 30% treated with emavusertib achieved > 30% CR/CRh rate 25% Benchmark ~1.5X greater than the benchmark in FLT3i-naïve patients is for FLT3i-naïve patients 20% 21% CR/CRh rate 15% 9 of 12 patient
Slide 28: FLT3m AML data presented at ASCO/EHA 2024
FLT3m AML data presented at ASCO/EHA 2024 Duration on Treatment CR CR MLFS went to SCT CR → went to SCT 6 of 12 patients ongoing CRh → achieved objective response ongoing MLFS → ongoing → ongoing → Not Evaluable 0 days 50 100 150 200 250 300 Days on Treatment Data include all patients in target popu
Slide 29: Strategy in AML
Strategy in AML ❶ Demonstrate safety 123 patients1 treated in TakeAim AML Ph 1/2 study, acceptable safety profile established ❷ Demonstrate single-agent activity Single-agent activity observed; next step is to confirm these initial findings in a larger number of patients ❸ Pursue fastest path to 1st
Slide 30: Emavusertib in All Comers
Emavusertib in All Comers fen CUS’
Slide 31: Triplet Combination targets all comers in frontline AML
Triplet Combination targets all comers in frontline AML oncogenic IRAK4-L is expressed emavusertib synergy with aza/ven ema/aza/ven in nearly all AML patients in preclinical studies triplet combination 800 Preclinical Data All Comers Model Relative cell growth in AML cell lines (THP-1) treated for 9
Slide 32: Summary in AML
Summary in AML Leukemia • Emavusertib targets both FLT3 and IRAK4 • Emavusertib offers potential for best-in-class therapeutic in FLT3m AML (a genetically-defined population) • Oncogenic IRAK4 is expressed in nearly all AML patients and is not addressed by current standard-of-care (azacitidine and v
Slide 33: Solid Tumors
Solid Tumors fen CUS’
Slide 34: Emavusertib is being evaluated in several solid tumor Investigator Sponsored Trials (ISTs)
Emavusertib is being evaluated in several solid tumor Investigator Sponsored Trials (ISTs) Lead Investigator Indication Combination Sponsor Washington Univ St Louis – Grierson Pancreatic gemcitabine/nab-paclitaxel NCI Washington Univ St Louis – Grierson Gastro-Esophageal FOLFOX/PD1 +/- trastuzumab W
Slide 35: Other Information
Other Information fen CUS’
Slide 36: Financials and IP
Financials and IP We believe cash is sufficient to achieve anticipated As of June 30, 2024 milestones $28.4M Cash and investments1 • Updated PCNSL data 15-20 patients (late 2024) ~5.9M Shares Outstanding • AML triplet safety data (late 2024) ~7.0M Shares Fully Diluted 2035 Composition of Matter IP o